Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
RARE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.02 - $60.37
Previous CloseN/A
Volume75.38K
Average Volume (3M)857.14K
Market Cap
$4.03B
Enterprise Value$5.60B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 01, 2025EPS Estimate
-1.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.34
Shares Outstanding92,344,270
10 Day Avg. Volume729,219
30 Day Avg. Volume857,137
Standard Deviation0.14
R-Squared0.05
Alpha-0.00120
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.71
Price to Cash Flow (P/CF)-15.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.39
Enterprise Value/Ebitda-12.13
Forecast
1Y Price Target
$92.87Price Target Upside109.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement is prepared to launch UX111 upon its potential FDA approval, marking a key milestone for the company.
Regulatory ApprovalThe FDA has accepted the BLA of UX111 for Priority Review under an accelerated approval pathway, indicating a significant regulatory milestone for Ultragenyx.
Bears Say
Investment RisksThere are risks to the investment thesis, including potential clinical trial failures, failure to secure regulatory approvals, and smaller than anticipated commercial opportunities.
---
Ownership Overview
3.93% Insiders
29.90% Mutual Funds
35.75% Other Institutional Investors
16.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $37.02 and its highest was $60.37 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $4.03B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is May 01, 2025 which is in 69 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Feb 13, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.308 by -$0.082.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.53.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 92,344,270 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.308. Following the earnings report the stock price went down -2.367%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
---
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.87 (109.69% Upside)
$92.87 (109.69% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 265.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $908.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.46%
12-Months-Change
Fundamentals
Return on Equity
-214.50%
Trailing 12-Months
Asset Growth
0.43%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Company Deck
---
RARE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and successful international expansion, alongside notable advancements in clinical programs. However, significant net losses and high operating expenses present financial challenges. The positive highlights slightly outweigh the concerns, indicating a cautiously optimistic outlook.Read More>---
RARE Stock 12 Month Forecast
Average Price Target
$92.87
▲(109.69% Upside)
Technical Analysis
Amicus
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering RARE
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
-0.27%
reiterated a buy rating 8 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of -0.27% per trade.
---